University of Florida
Gainesville, Florida, 32608, United States
Location status: Recruiting
Location contact
Jennifer Hagen, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06046859
With this prospective double-blinded, placebo controlled clinical trial we hypothesize that immediate (post-injury) intervention with Fluoxetine will prevent/mitigate the development of negative psychiatric symptomology such as PTSD and depression for victims of bodily trauma. We also hypothesize that immediate use of Fluoxetine will decrease subjects' pain, pain interference and opioid use without changing our standard of care post-injury pain medication regimen. Enrolled subjects will be randomized to Fluoxetine or placebo at their index hospitalization.
Interested in participating?
Request Info18 year–85 year
All sexes
Interventional
Phase 4
Gainesville, Florida, 32608, United States
Location status: Recruiting
Jennifer Hagen, MD
PRINCIPAL_INVESTIGATOR
Upwards of 40-85% survivors of bodily trauma (in the civilian world most commonly motor vehicle accidents, falls and assaults), develop moderate to severe negative psychiatric symptomology following their injuries. (2,7) This symptomology can persist for years; at least 20% of patients with musculoskeletal trauma, specifically, display symptomology consistent with post-traumatic stress disorder (PTSD) symptomology up to three years following their injury. (8) Poor mental health outcomes are an independent risk factor for poor physical and social outcomes. (9,10) These symptoms, which are highly impairing, are complicated and heightened by loss of work/income following trauma, limited financial and social resources, and a large percentage of the population being uninsured/underinsured. Research has demonstrated that the pressures of poverty and low socioeconomic status alone predispose to PTSD symptomology and poor coping mechanisms, and this is compounded by decreased ability to obtain and pay for mental health care by those impoverished. There are significant barriers to mental health care for many adults, and these hurdles are even more insurmountable for those under or uninsured, minorities, and those in rural communities. (11) Very few victims of trauma who screen positive for psychological disorder receive mental health services following injury (12% at 3-months from injury), and if so, it is far removed from the injury (22% at 24-months from injury).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
Time frame: Baseline up to 12 months
BDI-II Beck Depression Inventory: higher score means worse outcome; 0-63.
Time frame: Baseline up to 12 months
PROMIS PI: Pain Interference; A score of 50 is average; Adaptive so no minimum/maximum values.
Contact information is provided by the study sponsor or research team.
Jennifer Hagen, MD
CONTACT
MaryBeth Horodyski, EdD
CONTACT
University of Florida
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05989230
Chronic Pain, Musculoskeletal Injury
Baltimore, Maryland, United States
View Trial DetailsNCT06635668
ACL Injury, Anterior Cruciate Ligament Injuries
Fargo, North Dakota, United States
View Trial DetailsNCT07145645
Knee Injuries, Leg Injuries
Calgary, Alberta, Canada
View Trial DetailsNCT05780502
Musculoskeletal Injury
Charlotte, North Carolina, United States
View Trial Details